| Literature DB >> 26546267 |
Stefan Kärst1, Danny Arends1, Sebastian Heise1, Jan Trost1, Marie-Laure Yaspo2, Vyacheslav Amstislavskiy2, Thomas Risch2, Hans Lehrach2, Gudrun A Brockmann3.
Abstract
BACKGROUND: We investigated parent-of-origin and allele-specific expression effects on obesity and hepatic gene expression in reciprocal crosses between the Berlin Fat Mouse Inbred line (BFMI) and C57Bl/6NCrl (B6N).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26546267 PMCID: PMC4636810 DOI: 10.1186/s12864-015-2164-2
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Phenotypes of 10 weeks old males and females of reciprocal crosses between BFMI and B6N with and without cross-fostering on high fat diet
| Phenotypes1 | F1(BFMI x B6N) | F1(B6N x BFMI) |
| |||
|---|---|---|---|---|---|---|
| BFMI father (patBFMI) | BFMI mother (matBFMI) | |||||
| Males | Females | Males | Females | Males | Females | |
| Maternal fostering | ||||||
| Body mass (g) | 34.23 (3.26) | 26.16 (2.02) | 36.82 (3.96) | 25.27 (2.06) | n.s. | n.s. |
| Fat mass (g) | 3.86 (1.49) | 3.34 (1.01) | 7.06 (2.56) | 3.44 (1.04) | 0.0037 | n.s. |
| Lean mass (g) | 27.54 (2.06) | 20.45 (1.00) | 26.93 (2.10) | 19.68 (1.09) | 0.0536 | 0.0855 |
| Fat / Lean mass ratio | 0.14 (0.05) | 0.16 (0.04) | 0.26 (0.08) | 0.17 (0.05) | 0.0009 | n.s. |
| Liver mass (g) | 1.55 (0.23) | 1.21 (0.10) | 1.68 (0.18) | 1.16 (0.12) | n.s. | n.s. |
| Liver triglycerides/ protein (μg/μg) | 0.45 (0.09) | 0.47 (0.11) | 0.59 (0.22) | 0.45 (0.08) | 0.0843 | n.s. |
| Blood glucose levels (mg/dl) | 165.33 (27.20) | 135.92 (12.22) | 174.25 (23.80) | 133.25 (10.71) | n.s. | n.s. |
| Cross-fostering | ||||||
| Body mass (g) | 34.27 (3.41) | 25.96 (3.75) | 35.63 (2.65) | 24.36 (1.71) | n.s. | n.s. |
| Fat mass (g) | 4.06 (2.06) | 3.45 (1.56) | 5.54 (1.74) * | 2.70 (0.99) | 0.0142 | n.s. |
| Lean mass (g) | 29.54 (1.84) ** | 21.69 (3.06) | 29.61 (1.68) ** | 20.64 (1.19) ° | n.s. | n.s. |
| Fat / Lean mass ratio | 0.14 (0.06) | 0.16 (0.07) | 0.19 (0.06) ** | 0.13 (0.04) ° | 0.0067 | n.s. |
| Liver mass (g) | 1.66 (0.21) | 1.22 (0.23) | 1.75 (0.15) | 1.17 (0.13) | n.s. | n.s. |
| Liver triglycerides/ protein (μg/μg) | 0.15 (0.09)** | 0.34 (0.17)° | 0.21 (0.08)** | 0.26 (0.13)** | 0.0307 | n.s. |
| Blood glucose levels (mg/dl) | 137.82 (19.07) ** | 130.36 (13.13) | 151.83 (22.7) * | 139.29 (20.64) | 0.0307 | n.s. |
1shown are means ± standard deviation after correction for litter size, except for blood glucose and liver triglycerides, which were not affected by the litter size. Asterisks additionally indicate significant effects of cross fostering on phenotypes comparing animals of the same direction of cross (patBFMI vs. cross-fostered patBFMI, matBFMI vs. cross-fostered matBFMI) (**p < 0.01, *p < 0.05, °p < 0.1)
Fig. 1Development of phenotypes of males and females on a high fat diet of the two reciprocal F1-crosses until 10 weeks. The figures show means ± standard deviations of the total fat mass and the total fat mass-to-total-lean mass-ratios in F1-animals without (a and b, respectively) and with cross-fostering (c and d, respectively). Paternal and maternal BFMI (pat, mat) indicates direction of cross. Asterisks indicate significant differences between different reciprocal crosses for males (blue) and females (red) and significant differences within the same reciprocal cross between males and females of matBFMI (orange) and patBFMI (grey) (***p < 0.001, **p < 0.01, *p < 0.05)
KEGG pathways affected by the direction of cross in F1 males (p < 0.05)
| KEGG ID | Major category/Subcategory | Pathway Name | Proportion of genes in pathway | Identified genes 1 fold-change (matBFMI vs. patBFMI) | TFBS 2 | Corrected P-Value for pathway ORA |
|---|---|---|---|---|---|---|
|
| Organismal Systems/ Environmental adaptation | Circadian rhythm | 10 % | Arntl (0.54) | - | 0.00087 |
| Per2 (1.32) | - | |||||
| Per3 (1.71) | - | |||||
|
| Cellular Processes/Transport and catabolism | Peroxisome | 5 % | Abcd1 (1.22) | - | 0.00094 |
| Abcd2 (1.52) | - | |||||
| Acsl3 (1.22) | - | |||||
| Crat (1.27) | - | |||||
|
| Metabolism/Metabolism of cofactors and vitamins | Retinol metabolism | 5 % | Cyp2c38 (1.61) | Esrra, Esrrb | 0.00113 |
| Cyp2c39 (1.29) | Esrra, Esrrb | |||||
| Cyp4a10 (1.35) | ERE, IR3 | |||||
| Cyp4a14 (1.32) | - | |||||
|
| Metabolism/Lipid metabolism | Arachidonic acid metabolism | 4 % | Cyp2c38 (1.61) | Esrra, Esrrb | 0.00099 |
| Cyp2c39 (1.29) | Esrra, Esrrb | |||||
| Cyp4a10 (1.35) | ERE, IR3 | |||||
| Cyp4a14 (1.32) | - | |||||
|
| Metabolism/Lipid metabolism | Fatty acid degradation | 6 % | Acsl3 (1.22) | - | 0.00198 |
| Cyp4a10 (1.35) | ERE, IR3 | |||||
| Cyp4a14 (1.32) | - | |||||
|
| Metabolism/Lipid metabolism | Fatty acid biosynthesis | 14 % | Acsl3 (1.22) | - | 0.00282 |
| Fasn (1.22) | ERE | |||||
|
| Organismal Systems/ Endocrine system | PPAR signaling pathway | 4 % | Acsl3 (1.22) | - | 0.00617 |
| Cyp4a10 (1.35) | ERE, IR3 | |||||
| Cyp4a14 (1.32) | - | |||||
|
| Metabolism/ Lipid metabolism | Fatty acid elongation | 8 % | Acot4 (1.82) | - | 0.00627 |
| Elovl6 (1.32) | - | |||||
|
| Metabolism/Lipid metabolism | Steroid hormone biosynthesis | 4 % | Cyp2c38 (1.61) | Esrra, Esrrb | 0.00636 |
| Cyp2c39 (1.29) | Esrra, Esrrb | |||||
| Cyp7b1 (0.83) | - | |||||
|
| Metabolism/ Lipid metabolism | Biosynthesis of unsaturated fatty acids | 8 % | Acot4 (1.82) | - | 0.00635 |
| Elovl6 (1.32) | - | |||||
|
| Organismal Systems/Circulatory system | Vascular smooth muscle contraction | 2 % | Avpr1a (0.77) | - | 0.01549 |
| Cyp4a10 (1.35) | ERE, IR3 | |||||
| Cyp4a14 (1.32) | - | |||||
|
| Environmental information processing/Membrane transport | ABC transporters | 4 % | Abcd1 (1.22) | - | 0.01649 |
| Abcd2 (1.52) | - | |||||
|
| Metabolism/ Lipid metabolism | Linoleic acid metabolism | 4 % | Cyp2c38 (1.61) | Esrra, Esrrb | 0.01884 |
| Cyp2c39 (1.29) | Esrra, Esrrb | |||||
|
| Organismal systems/Immune system | Hematopoietic cell lineage | 2 % | Dntt (1.24) | - | 0.04814 |
| Il1r1 (0.74) | - |
1P-value for differential gene expression between reciprocal F1 groups of males was p < 0.05, minimum fold-change difference >20 %, The innateDB tool was used for the KEGG pathway analysis. matBFMI – BFMI mother, patBFMI – BFMI father
2Steroid hormone transcription factor binding sites. Esrra/b – estrogen related receptor a/b, ER – estrogen receptor alpha, ERE – estrogen response element, IR3 - androgen inverted repeats of hexameric half-site separated by 3 bp of spacer
Genes highly differentially expressed between the reciprocal F1 males (p < 0.05, fch > 20 %)
| Gene Symbol1 | Chr | Gene description | Mean RPKM2 | Fch matBFMI/ | t Test | TFBS3 | |
|---|---|---|---|---|---|---|---|
| patBFMI | matBFMI | patBFMI | |||||
|
| 10 | solute carrier family 16 (monocarboxylic acid transp.), 7 | 1.91 | 2.30 | 1.20 | 0.0007 | Esrrb |
| Nlrp12 | 7 | NLR family, pyrin domain containing 12 | 2.66 | 2.19 | 0.82 | 0.0009 | ERE |
| Il1r1 | 1 | interleukin 1 receptor, type I | 2.16 | 1.60 | 0.74 | 0.0019 | - |
| St5 | 7 | suppression of tumorigenicity 5 | 1.97 | 1.61 | 0.82 | 0.0029 | - |
|
| 13 | 3-hydroxy-3-methylglutaryl-Coenzyme A reductase | 3.01 | 3.98 | 1.32 | 0.0034 | - |
| Scara5 | 14 | scavenger receptor class A, member 5 (putative) | 1.23 | 0.55 | 0.44 | 0.0050 | - |
| Gpr110 | 17 | G protein-coupled receptor 110 | 1.48 | 0.85 | 0.57 | 0.0092 | - |
| Grem2 | 1 | gremlin 2 homolog, cysteine knot superfamily | 1.50 | 1.11 | 0.74 | 0.0102 | - |
|
| 11 | fatty acid synthase | 4.47 | 5.41 | 1.21 | 0.0110 | ERE |
| Selenbp2 | 3 | selenium binding protein 2 | 5.72 | 4.76 | 0.83 | 0.0113 | - |
|
| 4 | cytochrome P450, family 4, subfam. a, polypept. 14 | 3.58 | 4.74 | 1.32 | 0.0119 | - |
|
| 19 | cytochrome P450, family 2, subfamily c, polypet. 38 | 1.46 | 2.33 | 1.60 | 0.0122 | Esrra, Esrrb |
|
| 2 | carnitine acetyltransferase | 1.79 | 2.27 | 1.26 | 0.0128 | - |
|
| 1 | coenzyme Q10 homolog B (S. cerevisiae) | 1.42 | 1.98 | 1.39 | 0.0138 | - |
| Rai14 | 15 | retinoic acid induced 14 | 1.98 | 1.64 | 0.83 | 0.0144 | - |
| Mup-ps20 | 4 | major urinary protein, pseudogene 20 | 1.46 | 0.51 | 0.35 | 0.0145 | - |
| Arntl | 7 | aryl hydrocarbon receptor nuclear translocator-like | 1.90 | 1.05 | 0.55 | 0.0151 | - |
|
| 4 | acyl-coenzyme A amino acid N-acyltransferase 2 | 2.37 | 3.22 | 1.36 | 0.0155 | Esrrb, IR3 |
|
| 15 | ATP-binding cassette, sub-family D (ALD), 2 | 1.14 | 1.72 | 1.51 | 0.0157 | - |
|
| 19 | cytochrome P450, family 2, subfamily c, polypept.39 | 2.77 | 3.57 | 1.29 | 0.0157 | Esrra, Esrrb |
| Slc45a3 | 1 | solute carrier family 45, member 3 | 2.15 | 1.72 | 0.80 | 0.0166 | - |
| Sntg2 | 12 | syntrophin, gamma 2 | 1.75 | 1.45 | 0.83 | 0.0187 | - |
|
| 1 | period circadian clock 2 | 1.26 | 1.67 | 1.32 | 0.0208 | - |
|
| 3 | hyperpolarization-activated, cyclic nucleotide-gated | 0.95 | 1.51 | 1.60 | 0.0208 | - |
|
| 8 | growth arrest specific 6 | 2.26 | 2.73 | 1.21 | 0.0209 | - |
| Serpina12 | 12 | ser/cys peptidase inhibitor, member 12 | 2.40 | 1.94 | 0.81 | 0.0211 | - |
|
| 3 | ELOVL family member 6, elongation of LCFA | 3.20 | 4.17 | 1.30 | 0.0214 | - |
|
| 1 | acyl-CoA synthetase long-chain family member 3 | 2.24 | 2.71 | 1.21 | 0.0215 | - |
|
| 12 | acyl-CoA thioesterase 4 | 0.93 | 1.66 | 1.79 | 0.0219 | - |
|
| 2 | solute carrier family 20, member 1 | 1.54 | 1.87 | 1.21 | 0.0219 | - |
| B3galt1 | 2 | UDP beta 1,3-galactosyltransferase, polypept.1 | 1.52 | 1.07 | 0.70 | 0.0230 | - |
| Cyp7b1 | 3 | cytochrome P450, family 7, subfamily b, polypept. 1 | 5.11 | 4.23 | 0.83 | 0.0257 | - |
|
| 4 | cytochrome P450, family 4, subfamily a, polypept.10 | 3.78 | 5.02 | 1.33 | 0.0260 | ERE, IR3 |
1Bold gene symbols indicate up regulation in F1 males of a BFMI mother. A list of all differentially expressed genes (p < 0.1) is given in Additional file 1: Table S1. Chr – chromosome, matBFMI – BFMI mother, patBFMI – BFMI father, Fch – fold-changes
2All values were log-transformed (ln)
3TFBS - Transcription factor binding sites for steroid hormones. Esrrb – estrogen related receptor b, ERE – estrogen response element, IR3 – androgen inverted repeats of hexameric half-site separated by 3 bp of spacer
Fig. 2Differential gene expression comparing F1 males from reciprocal crosses and parental strains. Heatmap of genes that were differentially expressed between the reciprocal crosses (p < 0.05) and parental strain gene expression for KEGG pathways of a) biosynthesis of unsaturated fatty acids and b) fatty acid degradation
Differentially expressed genes between patBFMI and matBFMI on X chromosome and mitochondria
| Gene Symbol1 | Chr | Gene Description (mgi) | Mean RPKM2 | Fch matBFMI/ | tTest F1 | TFBS3 | |
|---|---|---|---|---|---|---|---|
| patBFMI | matBFMI | ||||||
| Trmt2b | X | TRM2 tRNA methyltransferase 2B | 2.07 | 1.83 | 0.88 | 0.0008 | - |
| Ssr4 | X | signal sequence receptor, delta | 3.01 | 2.84 | 0.94 | 0.0013 | - |
| Rps4x | X | ribosomal protein S4, X-linked | 4.3 | 4.17 | 0.97 | 0.0026 | - |
| Prdx4 | X | peroxiredoxin 4 | 3.63 | 3.49 | 0.96 | 0.0086 | - |
| Shroom2 | X | shroom family member 2 | 1.66 | 1.46 | 0.88 | 0.0163 | - |
| Rps24-ps3 | X | ribosomal protein S24, pseudogene 3 | 5.17 | 5.04 | 0.97 | 0.0212 | - |
|
| X | predicted pseudogene 5763 | 0.85 | 1.52 | 1.79 | 0.0255 | - |
|
| X | NAD(P) dependent steroid dehydrogenase-like | 3.15 | 3.47 | 1.10 | 0.0331 | - |
|
| X | ATP-binding cassette, sub-family D (ALD), 1 | 1.37 | 1.67 | 1.22 | 0.0439 | - |
| Mospd2 | X | motile sperm domain containing 2 | 1.92 | 1.88 | 0.98 | 0.0456 | - |
|
| X | HAUS augmin-like complex, subunit 7 | 1.85 | 2.23 | 1.21 | 0.0486 | Esrrb |
|
| X | CD99 antigen-like 2 | 1.77 | 1.87 | 1.06 | 0.0489 | Esrra,Esrrb |
|
| X | serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 | 2.01 | 2.52 | 1.25 | 0.0508 | ERE |
| Pls3 | X | plastin 3 (T-isoform) | 2.84 | 2.74 | 0.96 | 0.0557 | - |
| Tsc22d3 | X | TSC22 domain family, member 3 | 3.59 | 3.20 | 0.89 | 0.0667 | ADR3 |
| Slc16a2 | X | solute carrier family 16 (monocarboxylic acid transporters), member 2 | 2.77 | 2.62 | 0.95 | 0.0668 | - |
|
| X | androgen receptor | 0.26 | 0.62 | 2.38 | 0.0678 | - |
|
| X | hydroxysteroid (17-beta) dehydrogenase 10 | 4.21 | 4.43 | 1.05 | 0.0688 | - |
| Tmsb4x | X | thymosin, beta 4, X chromosome | 3.8 | 3.63 | 0.96 | 0.0703 | IR3 |
|
| X | glycerol kinase | 2.9 | 2.97 | 1.02 | 0.0790 | Esrra,Esrra, ERE |
|
| X | predicted gene 14760 | 3.02 | 3.18 | 1.05 | 0.0803 | Esrra,Esrrb |
|
| X | WD repeat domain 13 | 1.62 | 1.7 | 1.05 | 0.0831 | Esrra, ERE |
| Gm14373 | X | predicted gene 14373 | 2.49 | 2.41 | 0.97 | 0.0858 | - |
|
| X | claudin 2 | 3.22 | 3.45 | 1.07 | 0.0870 | - |
| Rlim | X | ring finger protein, LIM domain interacting | 2.2 | 2.12 | 0.96 | 0.0910 | - |
| Zfx | X | zinc finger protein X-linked | 1.47 | 1.23 | 0.84 | 0.0915 | - |
|
| X | polyglutamine binding protein 1 | 2.53 | 2.70 | 1.07 | 0.0971 | - |
| Lamp2 | X | lysosomal-associated membrane protein 2 | 4.14 | 4.01 | 0.97 | 0.0974 | Esrra,Esrrb |
| F8 | X | coagulation factor VIII | 1.99 | 1.83 | 0.92 | 0.0979 | - |
| Gm6472 | X | predicted pseudogene 6472 | 4.99 | 4.90 | 0.98 | 0.0997 | - |
| mt-Nd1 | MT | mitochondrially encoded NADH dehydrogenase 1 | 6.76 | 6.42 | 0.95 | 0.0165 | - |
1Bold gene symbols indicate up-regulation in matBFMI. Y chromosomal genes were not differentially expressed. Chr – chromosome, matBFMI – BFMI mother, patBFMI – BFMI father, Fch – fold-change
2All values were log-transformed (ln)
3TFBS - Transcription factor binding sites for steroid hormones. Esrrb – estrogen related receptor b, ERE – estrogen response element, ADR3 – androgen direct repeats of the hexameric half-site, IR3 – androgen inverted repeats of hexameric half-site separated by 3 bp of spacer
SNPs indicating allelic imbalance in both reciprocal crosses
| Alternative allele1 proportion | ||||||||
|---|---|---|---|---|---|---|---|---|
| Chr | SNP-Position | Ref/Alt | Gene symbol | Gene description | patBFMI | matBFMI | Ratio diff. | TFBS2 |
| 2 | 91712576 | C/T | Harbi1 | harbinger transposase derived 1 | 48.1 | 79.7 | 31.5 | Esrra, Esrrb |
| 2 | 152687856 | C/T | Mcts2 | malignant T cell amplified sequence 2 | 88.9 | 7.2 | 81.8 | - |
| 2 | 152704657 | A/T | H13 | histocompatibility 13 | 18.4 | 75.9 | 57.5 | - |
| 2 | 152705549 | G/A | H13 | 7.9 | 100.0 | 92.1 | ||
| 7 | 6704437 | C/T | Peg3 | paternally expressed 3 * | 93.6 | - | - | - |
| 7 | 6706584 | A/G | Peg3 | 100.0 | - | - | ||
| 11 | 22956525 | G/A | Commd1 | COMM domain containing 1 | 37.3 | 57.7 | 20.3 | - |
| 11 | 22972794 | G/T | Commd1 | 98.8 | 0.0 | 98.8 | ||
| 11 | 22974882 | G/A | Zrsr1 | zinc finger (CCCH type), RNA binding motif and serine/arginine rich 1 | 95.2 | 4.6 | 90.7 | - |
| 11 | 109933190 | T/C | Abca8b | ATP-binding cassette, sub-family A (ABC1), member 8b | 57.6 | 30.9 | 26.7 | - |
| 11 | 109933214 | C/T | Abca8b | 60.8 | 38.5 | 22.4 | ||
| 11 | 109974591 | A/C | Abca8b | 67.7 | 45.7 | 22.0 | ||
| 12 | 104081368 | A/G | Serpina4-ps1 | serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1 | 24.6 | 60.9 | 36.3 | - |
| 12 | 104081522 | G/A | Serpina4-ps1 | 27.2 | 58.0 | 30.8 | ||
| 17 | 12380069 | G/T | Plg | plasminogen | 22.6 | 71.7 | 49.1 | - |
| 17 | 78969687 | T/C | Prkd3 | protein kinase D3 | 77.5 | 57.3 | 20.2 | - |
Chr – chromosome, matBFMI – F1 males from BFMI mothers, patBFMI – F1 males from BFMI fathers; * Coverage thresholds for ChiSquare based difference calculations in Peg3 were not met in all matBFMI samples. However, variant calling annotates all matBFMI samples as reference (B6) at these positions, confirming the paternal expression. Further ASE gene details are given in Additional file 2: Table S2
1Alternative allele in these cases is the BFMI allele
2TFBS - Steroid hormone transcription factor binding sites. Esrra/b – estrogen related receptor a/b, ERE – estrogen response element